NCT04858009View on ClinicalTrials.gov

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Metastatic Pancreatic CarcinomaStage IV Pancreatic Cancer AJCC V8Metastatic Malignant Neoplasm in the Peritoneum
Interventions
DRUG

Cisplatin

Given via HIPEC

DRUG

Hyperthermic Intraperitoneal Chemotherapy

Undergo HIPEC with mitomycin and cisplatin

DRUG

Nab-paclitaxel

Given via HIPEC

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET scan

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04858009 - Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis | Biotech Hunter | Biotech Hunter